Anesth Analg 2007 104: 378-383.
[Abstract]
[Full Text]
[PDF]
IMPLICATIONS: Lipid A, the toxic moiety of endotoxin, is linked to complications after cardiac surgery. We studied the safety and efficacy of eritoran (a lipid A antagonist) in a Phase II, double-blind, multicenter, clinical trial. Blocking lipid A with eritoran does not appear to confer any clear benefit in this setting.